Novartis To File Zelmac For Irritable Bowel Syndrome In 1999-2000

Novartis' irritable bowel syndrome therapy Zelmac (tegaserode) is one of four new therapies the firm plans to file with FDA in 1999-2000, Novartis Chairman designate and CEO Daniel Vasella indicated at a review of the company's 1998 financial results in London March 16.